Mortality in women with pregnancy-associated malignant melanoma - 15/11/14
, Therese M-L. Andersson, PhD a, Anna Plym, MSc a, Gustav J. Ullenhag, MD, PhD b, Henrik Møller, Dr Med c, Mats Lambe, MD, PhD a, dAbstract |
Background |
Malignant melanoma (MM) is one of the most common malignancies in young women. It remains debated whether a MM diagnosed during pregnancy or lactation has a worse prognosis.
Objective |
We sought to examine mortality in women with pregnancy-associated MM (PAMM) (diagnosed during pregnancy and up to 2-years postpartum).
Methods |
This was a population-based cohort study based on information retrieved from the Swedish Cancer and Multi-Generation Registers. Hazard ratios with 95% confidence intervals adjusted for age, period, education, parity, and tumor location were estimated.
Results |
In total, 6857 women and girls aged 15 to 44 years with a diagnosis of cutaneous MM between 1963 and 2009 were identified. Of these, 1019 cases were classified as PAMM. The cause-specific mortality did not differ between PAMM and MM not diagnosed near childbirth (adjusted hazard ratio 1.09, 95% confidence interval 0.83-1.42).
Limitations |
Information on stage at diagnosis was available only for a subset of patients
Conclusion |
Overall, the cause-specific mortality in women and girls with PAMM did not differ from that in women and girls with non-PAMM. The current findings do not provide evidence of an adverse prognostic influence of pregnancy or a recent birth.
Le texte complet de cet article est disponible en PDF.Key words : malignant melanoma, mortality, pregnancy, stage, survival, Sweden
Abbreviations used : CI, FPM, HR, MM, PAMM
Plan
| Supported by a grant from Karolinska Institutet Funds. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 6
P. 1093-1101 - décembre 2014 Retour au numéro
Article précédent
- Primary dermal melanoma: A unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma : A clinical, histologic, and gene expression–profiling study
- Michael Sidiropoulos, Roxana Obregon, Chelsea Cooper, Lauren Meldi Sholl, Joan Guitart, Pedram Gerami
- Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
- Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, Christian Posch, Kim Chong, Katia Johnston, Melissa Meier, Simona Osella-Abate, Pietro Quaglino, Adil Daud, Alain Algazi, Klemens Rappersberger, Susana Ortiz-Urda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?